Achaogen

PharmaceuticalsSeries DSan Francisco, USachaogen.com

Latest round

Series D

Last raised

Nov 2013

Total raised

$127M

Investors

8

About Achaogen

Founded in 2004 and based in San Francisco, US, Achaogen, Inc. is a biopharmaceutical company that is focused on the discovery, development, and commercialization of broad-spectrum antibiotics to treat multi-drug resistant bacterial infections.

Who invested in Achaogen

8 investors across 5 rounds

See all investors in Achaogen

Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.

Funding rounds

  1. Series D

    Nov 21, 2013

    Amount

    $10M

    Investors

    Locked

  2. Series D

    Mar 6, 2013

    Amount

    $19M

    Investors

    Locked

  3. Series C

    Apr 7, 2010

    Amount

    $56M

    Investors

    Locked

  4. Series B

    Oct 10, 2006

    Amount

    $26M

    Investors

    Locked

  5. Series A

    Aug 1, 2004

    Amount

    $16M

    Investors

    Locked

Questions about Achaogen

Who invested in Achaogen?

Achaogen has 8 investors on record across 5 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.

How much funding has Achaogen raised?

Achaogen has raised 5 venture rounds. Sign up free to see how much each round raised and the total.

When did Achaogen last raise money?

Achaogen's most recent round on record is a Series D, in Nov 2013.

What does Achaogen do?

Founded in 2004 and based in San Francisco, US, Achaogen, Inc.

Where is Achaogen headquartered?

Achaogen is headquartered in San Francisco, US.

Which VCs invest in companies like Achaogen?

Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back pharmaceuticals companies at Achaogen's stage. Their profiles are linked below.

Raising like Achaogen? Find the right VCs.

Capital Atlas matches your startup to active investors by stage, sector and region.

Free to start. Upgrade when you're ready to reach out.